One of the best connected biotech startups in Boston snags a plum discovery deal with Novartis
Novartis’ drug discovery crew inside the NIBR campus in Cambridge, MA is putting $30 million on the table to get a new TCR immuno-oncology program kicked off with one of the recent startups to debut in the field — serious money for what they believe can offer an effective approach to tackling solid tumors.
Christoph Westphal’s latest biotech creation, TScan, lined up the deal, which drew in a Novartis crew attracted by their approach in developing TCR-engineered T cell therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.